Antidepressant Therapies Is Fastest Growing Segment Fueling The Growth Of Serotonin Norepinephrine Inhibitor Market
Serotonin Norepinephrine Inhibitor Market The Global Serotonin Norepinephrine Inhibitor Market is estimated to be valued at US$ 6.53 Bn in 2023 and is expected to exhibit a CAGR of 3.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Serotonin-norepinephrine reuptake inhibitors (SNRIs) are a class of antidepressant medications that help treat major depressive disorder, generalized anxiety disorder, fibromyalgia and neuropathic pain by increasing levels of serotonin and norepinephrine in the brain. SNRIs have advantages over SSRIs as they act on both serotonin and norepinephrine rather than just serotonin alone. Market key trends: One of the emerging trends in the serotonin norepinephrine inhibitors market is the increased R&D activities for developing new treatment therapies combining multiple drug product types. Numerous clinical trials are currently underway to study the therapeutic efficacy...